Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatitis D

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    381 result(s) found for: Hepatitis D. Displaying page 4 of 20.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005563-27 Sponsor Protocol Number: VTI-208 Start Date*: 2013-07-26
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-induced liver decompensation (AILD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004243-39 Sponsor Protocol Number: VHCRP1401 Start Date*: 2016-11-17
    Sponsor Name:University of New South Wales Australia
    Full Title: A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection.
    Medical condition: Recent hepatitis C virus infection all genotypes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004864-38 Sponsor Protocol Number: P05411 Start Date*: 2009-10-02
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    13.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    13.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    13.1 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004095-10 Sponsor Protocol Number: V419-005 Start Date*: 2012-02-20
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Conco...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005143-24 Sponsor Protocol Number: M14-004 Start Date*: 2015-07-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1...
    Medical condition: Hepatitis C Virus Infection Human Immunodeficiency Virus Infection Chronic Hepatitis C Compensated Cirrhosis and Non-cirrhotics
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004108-39 Sponsor Protocol Number: V419-006 Start Date*: 2012-02-20
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: A Phase III Randomized, Partially Double-Blind, Active- Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy I...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005560-13 Sponsor Protocol Number: Hep-Net-HIDIT-2 Start Date*: 2009-06-12
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The ...
    Medical condition: To compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placeb...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10047455 Viral hepatitis B without mention of hepatic coma, with hepatitis delta LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019378-34 Sponsor Protocol Number: AI444-011 Start Date*: 2010-09-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004134-26 Sponsor Protocol Number: sof-crio Start Date*: 2015-02-19
    Sponsor Name:Centro Masve -Università degli Studi di Firenze-AOUC
    Full Title: A MULTICENTER, PROSPECTIVE, SINGLE ARM, OPEN-LABEL, PILOT STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF SOFOSBUVIR FOR SYMPTOMATIC MIXED CRYOGLOBULINEMIA
    Medical condition: HCV chronic hepatitis and Mixed Cryoglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    17.1 100000004866 10027756 Mixed cryoglobulinemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022568-11 Sponsor Protocol Number: AI452-008 Start Date*: 2011-04-20
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022408-28 Sponsor Protocol Number: AI444-031 Start Date*: 2010-12-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection.
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003573-10 Sponsor Protocol Number: 2012GA03 Start Date*: 2013-11-07
    Sponsor Name:University of Dundee & NHS Tayside
    Full Title: Can Vitamin D supplementation improve Hepatitis C cure rates: A pilot multicentre randomised controlled clinical trial
    Medical condition: Hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10065051 Acute hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024557-36 Sponsor Protocol Number: VHCRP1007 Start Date*: 2012-05-29
    Sponsor Name:The Kirby Institute
    Full Title: A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV...
    Medical condition: Chronic Hepatitis C genotype 2 and 3 infection.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021628-84 Sponsor Protocol Number: VX-950-C211 Start Date*: 2011-03-29
    Sponsor Name:Tibotec BVBA
    Full Title: A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot...
    Medical condition: Hepatitis C Virus (HCV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) SE (Completed) AT (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001125-13 Sponsor Protocol Number: SAHIV-IMEA50 Start Date*: 2017-04-07
    Sponsor Name:IMEA (Institut de Médecine et d’Epidémiologie Appliquée)–Fondation Léon M’Ba
    Full Title: Pilot study - Short duration therapy of acute hepatitis C genotypes 1 or 4 in HIV-infected patients: efficacy and tolerability of grazoprevir 100mg/elbasvir 50mg during 8 weeks
    Medical condition: Acute hepatitis C (genotypes 1 or 4)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065051 Acute hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000859-10 Sponsor Protocol Number: ANRS HC 20 Start Date*: 2009-04-10
    Sponsor Name:ANRS
    Full Title: Etude pilote, multicentrique, évaluant l’efficacité d’un traitement anti VHC optimisé (induction par 360µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la réponse viro...
    Medical condition: Cet essai vise à étudier la réponse à un re-traitement optimisé de l’hépatite C chez des patients co-infectés VIH-VHC (génotype 1 et 4), non répondeurs aux premiers traitements pour le VHC.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003648-70 Sponsor Protocol Number: ML 19365 Start Date*: 2007-02-08
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 ...
    Medical condition: First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002328-10 Sponsor Protocol Number: TIGEM1-MPSVI Start Date*: 2018-10-29
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.
    Medical condition: The clinical trial will be conducted on patients with Mucopolysaccharidosis Type VI. MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal d...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000488-83 Sponsor Protocol Number: P03685 Start Date*: 2004-11-29
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response
    Medical condition: Chronic Hepatitis C, Genotype 1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) HU (Completed) LT (Completed) CZ (Completed) AT (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000274-37 Sponsor Protocol Number: PRI03C Start Date*: 2016-03-21
    Sponsor Name:MCM Vaccine B.V.
    Full Title: Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 year old Children Previously Vaccinated with a 2-dose or 3-dose Infants series and Toddler dose with VAXELIS...
    Medical condition: Vaxelis is indicated for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis and invasive diseases caused by Haemophilus ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10054187 Polio immunization LLT
    19.0 100000004865 10069543 Hemophilus influenzae type b immunization LLT
    19.0 100000004865 10069593 Pertussis immunization LLT
    19.0 100000004865 10054181 Hepatitis B immunization LLT
    19.0 100000004865 10054180 Diphtheria immunization LLT
    19.0 100000004865 10054183 Tetanus immunization LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:46:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA